HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Money

Earnings analysis, pricing strategy, and financial dynamics

Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
MoneyFiercePharma ↗
Lilly touts 'encouraging' early days for Foundayo obesity launch, even as GLP-1 pill appears to lag Novo's
As Eli Lilly gets off to the races with the launch of its flagship oral GLP-1 Foundayo, the Indianapolis drugm…
May 1, 2026
MoneyDrug Channels ↗
Where Gross-to-net Pressure Actually Lives After Launch
Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. Cindy explains that many gro…
May 1, 2026
Analysts focus on three programs in big year for Bristol Myers
MoneyEndpoints News ↗
Analysts focus on three programs in big year for Bristol Myers
Wall Street’s expectations for Bristol Myers Squibb’s upcoming slate of data readouts are reaching a fever pit…
Apr 30, 2026
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
MoneyBriefing
Avalyn’s $300M IPO Signals Renewed Appetite for Reformulation Plays
Avalyn Pharma priced its Nasdaq debut at the top of range, raising $300M to push inhaled versions of existing …
Apr 30, 2026
Roche Sits Out $29B Pharma Buying Frenzy, Citing Debt and Discipline
Money
Roche Sits Out $29B Pharma Buying Frenzy, Citing Debt and Discipline
As peers spent $29B in late-March M&A, Roche CEO Thomas Schinecker said high rates, no patent cliffs, and 19 d…
Apr 27, 2026
Avalyn’s $182M IPO: Leaning on Re‑Formulation to Reprice Old IPF Drugs
Money
Avalyn’s $182M IPO: Leaning on Re‑Formulation to Reprice Old IPF Drugs
Avalyn Pharma plans a $182M IPO to fund late‑stage trials for inhaled pirfenidone and nintedanib, signaling in…
Apr 25, 2026
← Newer Page 4 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.